Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novocure Ltd NVCR

Healthcare Medical Devices
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and... see more

Recent & Breaking News (NDAQ:NVCR)

Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research

Business Wire October 29, 2020

Novocure Reports Third Quarter 2020 Financial Results and Provides Company Update

Business Wire October 29, 2020

Novocure to Report Third Quarter 2020 Financial Results

Business Wire October 2, 2020

Novocure to Host Virtual Research & Development Day

Business Wire September 29, 2020

Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community

Business Wire September 25, 2020

US FDA Starting to Grant Fast-Track Designation for Glioblastoma Treatments

Livemoney September 16, 2020

Novocure to Participate in the 2020 Wells Fargo Virtual Healthcare Conference

Business Wire September 4, 2020

Novocure Announces Expansion of Its Executive Leadership Team

Business Wire August 13, 2020

Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update

Business Wire July 30, 2020

Novocure Announces Recipients of 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Business Wire July 28, 2020

First Patient Enrolled in Novocure's EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays

Business Wire July 22, 2020

Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer

Business Wire July 15, 2020

Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua(TM)

Business Wire July 8, 2020

Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer

Business Wire July 7, 2020

Novocure to Report Second Quarter 2020 Financial Results

Business Wire July 1, 2020

Novocure Announces Launch of MyLink(TM) to Enable Patient-Guided, Remote Download of Optune® Usage Data

Business Wire June 2, 2020

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

GlobeNewswire May 13, 2020

Novocure Reports First Quarter 2020 Financial Results and Provides Company Update

Business Wire April 30, 2020

Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I

Business Wire April 27, 2020

Novocure Provides Business Update Related to COVID-19

Business Wire April 3, 2020